

ForPatients

by Roche

Hepatocellular Carcinoma (HCC) Non-Small Cell Lung Cancer (NSCLC) Triple Negative Breast Cancer Small Cell Lung Carcinoma Bladder Cancer Urothelial Carcinoma

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03232593 ML39313

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT03232593 ML39313
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
All

Healthy Volunteers
No
